Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

被引：4
|
作者：
Penault-Llorca, Frederique Madeleine
Filleron, Thomas
Asselain, Bernard
Baehner, Frederick L.
Fumoleau, Pierre
Lacroix-Triki, Magali
Butler, Steven M.
Jamshidian, Farid
Cherbavaz, Diana B.
Shak, Steven
Roca, Lise
Sagan, Christine
Lemonnier, J.
Martin, Anne-Laure
Roche, Henri Hubert
机构：
[1] Ctr Jean Perrin, Clermont Ferrand, France
[2] Inst Claudius Regaud, Toulouse, France
[3] Curie Site Paris, Paris, France
[4] Genom Hlth Inc, Redwood City, CA USA
[5] Ctr Georges Francois Leclerc, Dijon, France
[6] Inst Reg Canc Montpellier Val dAurelle, Montpellier, France
[7] Inst Cancerol Ouest Site Rene Gauducheau, St Herblain, France
[8] R&D UNICANC, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.11052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11052
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
    Unal, Caglar
    Ozmen, Tolga
    Ordu, Cetin
    Pilanci, Kezban Nur
    Ilgun, Ahmet Serkan
    Gokmen, Erhan
    Almuradova, Elvina
    Ozdogan, Mustafa
    Guler, Niluefer
    Uras, Cihan
    Kara, Halil
    Demircan, Orhan
    Isik, Selver
    Alco, Gul
    Saip, Pinar
    Aydin, Esra
    Duymaz, Tomris
    Celebi, Filiz
    Yararbas, Kanay
    Soybir, Gursel
    Ozmen, Vahit
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score
    Bowles, Daniel W.
    Rabinovitch, Rachel
    Borges, Virginia
    Urquhart, Alexander
    Singh, Meenakshi
    Finlayson, Christina
    Elias, Anthony
    ONCOLOGY-NEW YORK, 2007, 21 (10): : 1212 - 1217
  • [43] The 21-Gene Recurrence Score Influences Treatment Recommendations for Patients With Node-Positive Breast Cancer
    Millien, Jeffanne
    Edwards, Claire
    Kaltman, Rebecca
    McSwain, Anita P.
    McGrail, Lisa
    Teal, Christine B.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 82 - 83
  • [44] Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer
    Woodward, Wendy A.
    Barlow, William E.
    Jagsi, Reshma
    Buchholz, Thomas A.
    Shak, Steven
    Baehner, Frederick
    Whelan, Timothy J.
    Davidson, Nancy E.
    Ingle, James N.
    King, Tari A.
    Ravdin, Peter M.
    Osborne, C. Kent
    Tripathy, Debasish
    Livingston, Robert B.
    Gralow, Julie R.
    Hortobagyi, Gabriel N.
    Hayes, Daniel F.
    Albain, Kathy S.
    JAMA ONCOLOGY, 2020, 6 (04) : 505 - 511
  • [45] Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2-breast cancer patients: results from the GEICAM/9906 trial.
    Martin, M.
    Brase, J. C.
    Ruiz-Borrego, M.
    Krappmann, K.
    Munarriz, B.
    Fisch, K.
    Ruiz, A.
    Weber, K. E.
    Crespo, C.
    Petry, C.
    Rodriguez, C. A.
    Kronenwett, R.
    Calvo, L.
    Alba, E.
    Carrasco, E.
    Casas, M.
    Caballero, R.
    Rodriguez-Lescure, A.
    CANCER RESEARCH, 2012, 72
  • [46] Impact of the Intermediate Oncotype DX Recurrence Score results on adjuvant treatment recommendations in hormone receptor-positive early breast cancer in a single center.
    De San Vicente, Borja Lopez
    Novas, Patricia
    Galve Calvo, Elena
    Fernandez, Sara
    Arrazubi, Virginia
    Angeles Sala, Maria
    Fernandez, Seila
    Arevalo, Alberto
    Fernando Arango, Juan
    Zumarraga, Ane
    Sande, Laura
    Teresa Perez-Hoyos, Maria
    Abad, Teresa
    Martinez del Prado, Purificacion
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
    Dowsett, Mitch
    Cuzick, Jack
    Wale, Christopher
    Forbes, John
    Mallon, Elizabeth A.
    Salter, Janine
    Quinn, Emma
    Dunbier, Anita
    Baum, Michael
    Buzdar, Aman
    Howell, Anthony
    Bugarini, Roberto
    Baehner, Frederick L.
    Shak, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1829 - 1834
  • [48] The impact of adjuvant chemotherapy on overall survival in hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis
    Kumar, Prashanth Ashok
    Wang, Dongliang
    Huang, Danning
    Sivapiragasam, Abirami
    CANCER RESEARCH, 2023, 83 (05)
  • [49] The effect of Oncotype DX® Recurrence Score on treatment recommendations for geriatric patients with early stage hormone receptor positive breast cancer
    Loftus, L.
    Acs, G.
    Kiluk, J.
    Laronga, C.
    Lee, M. C.
    Soliman, H.
    Boughey, J. C.
    Acs, P.
    Gordon, L.
    Sokol, G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S33 - S34
  • [50] COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR POSTMENOPAUSAL WOMEN WITH HR+/HER2-NODE-POSITIVE EARLY BREAST CANCER IN CANADA
    Berdunov, V
    Richardson, R.
    Millen, S.
    VALUE IN HEALTH, 2022, 25 (07) : S371 - S371
12345